Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oleclumab and Durvalumab in Multiple Sarcoma Subtypes
NCT04668300Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2020
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of oleclumab, durvalumab in angiosarcoma, dedifferentiated liposarcoma (DDL), osteosarcoma (OS), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2020; status: active, not recruiting.
02
Drugs
oleclumabdurvalumab
03
Conditions
angiosarcomadedifferentiated liposarcoma (DDL)osteosarcoma (OS)
Beyond the preview
Go deeper on NCT04668300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04668300.